Porphyromonas gingivalis lipids inhibit osteoblastic differentiation and function.
Porphyromonas gingivalis produces unusual sphingolipids that are known to promote inflammatory reactions in gingival fibroblasts and Toll-like receptor 2 (TLR2)-dependent secretion of interleukin-6 from dendritic cells. The aim of the present study was to examine whether P. gingivalis lipids inhibit osteoblastic function. Total lipids from P. gingivalis and two fractions, phosphoglycerol dihydroceramides and phosphoethanolamine dihydroceramides, were prepared free of lipid A. Primary calvarial osteoblast cultures derived from 5- to 7-day-old CD-1 mice were used to examine the effects of P. gingivalis lipids on mineralized nodule formation, cell viability, apoptosis, cell proliferation, and gene expression. P. gingivalis lipids inhibited osteoblast differentiation and fluorescence expression of pOBCol2.3GFP in a concentration-dependent manner. However, P. gingivalis lipids did not significantly alter osteoblast proliferation, viability, or apoptosis. When administered during specific intervals of osteoblast growth, P. gingivalis total lipids demonstrated inhibitory effects on osteoblast differentiation only after the proliferation stage of culture. Reverse transcription-PCR confirmed the downregulation of osteoblast marker genes, including Runx2, ALP, OC, BSP, OPG, and DMP-1, with concurrent upregulation of RANKL, tumor necrosis factor alpha, and MMP-3 genes. P. gingivalis total lipids and lipid fractions inhibited calvarial osteoblast gene expression and function in vivo, as determined by the loss of expression of another osteoblast differentiation reporter, pOBCol3.6GFPcyan, and reduced uptake of Alizarin complexone stain. Finally, lipid inhibition of mineral nodule formation in vitro was dependent on TLR2 expression. Our results indicate that inhibition of osteoblast function and gene expression by P. gingivalis lipids represents a novel mechanism for altering alveolar bone homeostasis at periodontal disease sites.
Wang
Yu-Hsiung
YH
Department of Craniofacial Sciences, University of Connecticut, School of Dental Medicine, Farmington, CT 06030, USA.
Jiang
Jin
J
Zhu
Qiang
Q
AlAnezi
Amer Z
AZ
Clark
Robert B
RB
Jiang
Xi
X
Rowe
David W
DW
Nichols
Frank C
FC
D016301:Alveolar Bone Loss / Q000209:etiology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D002518:Ceramides / Q000633:toxicity; D004983:Ethanolamines / Q000633:toxicity; D015870:Gene Expression / Q000187:drug effects; D008055:Lipids / Q000633:toxicity*; D051379:Mice; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D016966:Porphyromonas gingivalis / Q000737:chemistry / Q000472:pathogenicity*; D051195:Toll-Like Receptor 2 / Q000502:physiology
D002518:Ceramides; D004983:Ethanolamines; D008055:Lipids; C493486:Tlr2 protein, mouse; D051195:Toll-Like Receptor 2; C109343:dihydroceramide; C005448:phosphorylethanolamine